Article
[18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers.
Neurology - 7 Sept 2021
Wolters Emma E, Papma Janne M, Verfaillie Sander C J, Visser Denise, Weltings Emma, Groot Colin, van der Ende Emma L, Giannini Lucia A A, Tuncel Hayel, Timmers Tessa, Boellaard Ronald, Yaqub Maqsood, van Assema Danielle M E, Kuijper Dennis A, Segbers Marcel, Rozemuller Annemieke J M, Barkhof Frederik, Windhorst Albert D, van der Flier Wiesje M, Pijnenburg Yolande A L, Scheltens Philip, van Berckel Bart N M, van Swieten John C, Ossenkoppele Rik, Seelaar Harro
Abstract excerpt
OBJECTIVE: To assess the [18F]flortaucipir binding distribution across MAPT mutations in presymptomatic and symptomatic carriers. METHODS: We compared regional [18F]flortaucipir binding potential (BPND) derived from a 130-minute dynamic [18F]flortaucipir PET scan in 9 (pre)symptomatic MAPT mutation carriers (4 with P301L [1 symptomatic], 2 with R406W [1 symptomatic], 1 presymptomatic L315R, 1 presymptomatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
